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Abstract-Despite the considerable burden and costs of illness and despite the increasing need to set 
priorities on the basis of efficiency considerations, only 20 economic appraisals of asthma and COPD care 
have been published during the past 11 years. This paper provides a detailed summary of the 
cost-effectiveness ‘evidence’ given by these studies and a discussion of relevant methodological issues. The 
studies comparing programme costs of delivery methods for oxygen and for aerosol bronchodilator drugs, 
provide the most straightforward evidence in favour of the concentrator and the metered dose inhaler 
respectively. There also seems to be evidence in favour of hospital-based home care programmes as 
compared to community-based home care programs. Health education, especially directed at asthmatic 
children seems to reduce health care costs and improve attitude, compliance behaviour and self-manage- 
ment skills. Information on the cost-effectiveness of pharmacotherapy and diagnostic technologies, both 
important interventions in asthma and COPD, was found to be totally lacking. 
Key words--COPD, asthma, economic evaluation, review 
INTRODUCTION 
The pressing need for more efficient allocation of 
resources in health care has stimulated interest in 
economic evaluation studies. Whereas the first studies 
tended to concentrate on the most visible applications 
of modern advanced diagnostic and therapeutic tech- 
nology in medicine, the focus is gradually shifting to 
more routinely applied ‘small-ticket’ technologies. 
Although these are less expensive per unit of output, 
they often lead to much higher costs, because of their 
wide application in much larger patient populations, 
who often need long-term care. The treatment of 
asthma and chronic obstructive pulmonary disease 
(COPD) is characterized by such long-term, small- 
ticket, mostly drug therapy. 
The terminology of these two diagnoses is often 
confusing. In clinical practice patients frequently 
have overlapping characteristics and are not easily 
categorized as having either asthma or COPD. 
The Dutch practice is to treat asthma and COPD 
as different expressions of the same underlying dis- 
ease called chronic non-specific lung disease 
(CNSLD). However we will follow the English- 
language literature and report separately on asthma 
and COPD. COPD refers primarily to chronic 
bronchitis and emphysema. It causes progressive 
loss of lung function and is primarily related to 
long term cigarette smoking, age, occupational ex- 
posure and airways hyper-responsiveness. Asthma is 
characterized by attacks of dyspnea or wheezing, 
reversible airllow obstruction and hyper-responsive- 
ness [l]. 
In the Netherlands, the two conditions impair the 
quality of life of l&20% of men and 5510% of 
women and children. The associated burden of illness 
is considerable. The annual costs to society in the 
Netherlands are estimated to exceed 1 billion Dutch 
guilders. This includes health care costs and costs due 
to absence from work [2]. In the Netherlands, most 
asthma and COPD patients are treated by general 
practitioners (GPs). Almost 9% of all GP consul- 
tations and about 13% of all absenteeism due to 
illness is caused by asthma and COPD [2]. The ageing 
of the population will almost certainly lead to even 
larger costs of illness, especially due to COPD, in the 
near future. In children of 4-12 years of age asthma 
is the main reason for absence from school [3]. Also 
the number of hospitalizations due to asthma has 
been shown to be increasing significantly in children 
aged 14 [4]. Although they are generally considered 
to be of greater importance as a cause of disability 
and ill health than as a cause of death, asthma and 
COPD directly or indirectly cause 15% of all male 
mortality and 6% of all female mortality. 
Since the prevalence and associated burden and 
costs of asthma and COPD are large and are expected 
to grow in the near future, it seems important to 
establish the cost-effectiveness of the various health 
care interventions which are in common use. Econ- 
omic appraisals, by systematically comparing both 
the costs and the outcomes of alternative health care 
programmes, provide information on how to allocate 
scarce resources to obtain maximum positive health 
effects from those programmes. This article will re- 
view existing knowledge on the cost-effectiveness of
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asthma and COPD treatment and assess the quality 
of this information in a critical and constructive way. 
After describing the literature search, we review the 
topics of the studies and describe the nature of the 
economic appraisals. Then we deal with the alterna- 
tive treatments and what is known about their cost- 
effectiveness. The next sections review the 
measurement of outcomes and cost, followed by a 
thorough assessment of the quality of the effective- 
ness evidence on which the economic avaluations are 
based. The last section contains the conclusions and 
a discussion. 
SELECTION OF THE LITERATURE 
A medline search for publications in English found 
19 articles offering economic appraisals of a particu- 
lar asthma or COPD-related health care intervention 
15-231. A publication from the U.S. Office of Technol- 
ogy Assessment was added to this [24]. A combi- 
nation of the following entries was used: respiratory 
tract disease, obstructive lung disease, asthma, respir- 
atory therapy, respiratory drug therapy, economics, 
costs and cost-analysis, cost-benefit analysis and 
economic evaluation. The entry ‘cost-benefit analysis’ 
applied to all of the articles. The studies were all 
published between January 1980 and December 1991. 
NATURE OF THE ECONOMIC APPRAISALS 
Like Williams [25], who reviewed the psychosocial 
literature on COPD, we found that the majority of 
the economic evaluation studies published in inter- 
national journals have been peformed in the United 
States. Two studies were performed in the U.K., 1 in 
Australia, 1 in Germany and 1 in Sweden. 
A wide variety of COPD interventions have been 
subjected to an economic appraisal (see Table 1). 
Health educational programmes for adults and for 
children have been appraised relatively often. These 
programmes are primarily directed at asthmatics. 
Economic appraisals of pulmonary rehabilitation-a 
multidisciplinary programme which among other 
things includes physical exercise and health edu- 
cation-and of domiciliary oxygen therapy and home 
care, generally include patients with rather severe 
chronic airflow limitation. Aerosol bronchodilator 
delivery methods have been the subject of several 
studies involving asthma, COPD and other respir- 
atory diseases. We have not found a single economic 
appraisal of pharmacotherapy, which is the main 
treatment in asthma and COPD. 
Before we discuss the studies themselves, it is 
necessary to consider what constitutes an economic 
evaluation. Drummond et al. [26] make a useful 
distinction between partial evaluation and full econ- 
omic evaluation. Whereas partial evaluation studies 
are restricted to either costs or outcomes, or consider 
no alternatives to the intervention being studied, in 
full economic evaluations some combination of costs 
is compared with some combination of outcomes for 
two or more alternatives. Depending on the way in 
which the outcomes are assessed, a full economic 
evaluation is labelled a cost-minimization analysis, a 
cost-effectiveness analysis, a cost-utility analysis or a 
cost-benefit analysis [26,27]. A11 the articles reviewed 
have been labelled according to Drummond’s classifi- 
cation (see last column of Table 1). 
In a cost-minimization analysis the central question 
is restricted to ‘how to obtain the same outcome at 
the lowest cost?’ Equal effectiveness is explicitly as- 
sumed, backed up by evidence from good quality 
studies. For example, the studies by Lowson et al. [ 151 
and Scheffler et al. [24] concerning alternative ways of 
delivering oxygen and aerosol bronchodilator drugs, 
explicitly assumed that the alternatives were equally 
effective in terms of lung function and bronchodila- 
tion respectively. So the analyses concentrate on the 
assessment of the costs only. 
In contrast, the studies by M&eon et al. [16] and 
Motwani et al. [17], who also restricted their analyses 
to the costs only, were partial evaluation studies 
classified as cost -analyses. Motwani et al. in compar- 
ing home care with institutional care, and McKeon 
et al. in comparing the current practice of oxygen 
delivery with a rationalized programme, did not 
explicitly assume the equal effectiveness of these 
alternatives. Had they provided evidence for assum- 
ing equal effectiveness, their studies would have been 
labelled cost-minimization analyses. 
If the outcome is measured in units such as life 
years gained, walking distance, prevented reduction 
in forced expiration volumes or improvement in score 
on a quality of life scale, then the economic evalu- 
ation is called a cost-effectiveness analysis. For 
example, the study by Schmidt et al. [18] on mechan- 
ical ventilation for various groups of patients esti- 
mated that the costs per life year gained ranged from 
$460 for asthma patients to $2155 for patients suffer- 
ing from chronic bronchitis and emphysema. 
In a cost-utility analysis, benefits are expressed in 
quality adjusted life years (QALYs). A quality of life 
correction factor called utility is used to adjust life 
years for their quality. This utility reflects the prefer- 
ence value for a particular health state. Since improv- 
ing the quality of life might be seen as the ultimate 
goal of most asthma and COPD therapies, cost-utility 
analysis would be very appropriate to evaluate them. 
Although this is often recognised, only Toevs et al. 
[20] have attempted to measure this improvement in 
QALYs or ‘well years’ as they call them. They 
evaluated a behavioural programme directed at in- 
creasing compliance with a pulmonary rehabilitation 
programme and concluded that the programme pro- 
duced a ‘well year’ at a unit cost of $24,256. Also Hay 
et al. [ 121 in their study of AAT replacement therapy 
applied several values for the quality of a restricted 
activity day, but these values were not actually 
measured. Since QALYs can be seen as a common 
unit for measuring the outcome of diverse interven- 
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tions, cost-utility analysis has the potential additional 
advantage of allowing a comparison of interventions 
in asthma and COPD with those in other areas of the 
health care sector. 
Finally, if the outcome is measured in monetary 
units, the evaluation is labelled a cost-benejt analysis. 
This is often limited to a comparison of items that can 
easily be expressed in money terms, such as the 
number of outpatient visits or the number of hospi- 
talizations. Reviewing the literature, it became clear 
that there is a tendency to describe as cost-benefit 
analyses studies which concentrate on outcomes 
merely in terms of savings elsewhere in the health care 
sector. For example, in the study by Clark et al. [7] 
a sample of 310 low income urban children was 
randomly divided into a control group and an exper- 
imental group which received health education to 
improve asthma management at home. The costs of 
delivering the health education programme were 
compared to the outcomes in terms of health care 
cost savings mainly consisting of a reduced number 
of hospitalizations and emergency room visits. 
Although expecting a positive influence, the effect of 
health education on the ultimate goal of the interven- 
tion. i.e. improvement in quality of life, was not 
measured. As Guyatt et al. [27] and Drummond et al. 
[28] have shown, a cost-benefit analysis involves 
taking into account more than just the outcomes 
easily expressed in monetary units. It involves the 
monetary measurement of all relevant final outcomes, 
including health improvements. In fact none of the 
studies reviewed could be described as a full social 
cost-benefit analysis. 
In addition to Drummond’s classification, econ- 
omic appraisals can be divided into empirical econ- 
omic evaluation studies and studies based on 
modelling. In empirical evaluation studies, the econ- 
omic analysis is linked to a clinical study. Modelling 
studies are in fact secondary analyses in which cost 
and outcome data obtained from several previous 
studies are combined into an overall cost-effectiveness 
model. The studies by Lowson et al. and Hay et al. 
are good examples of the latter. 
ALTERNATIVES COMPARED 
Since economics is about choice, the point of 
departure for an economic evaluation is to specify the 
alternatives. In all studies, a comparison is made 
between two or more alternatives, although they are 
not always explicitly given. In 7 studies the alternative 
was ‘doing nothing’, which can be described more 
precisely as ‘continuing conventional or usual care’. 
Health education for adults 
Health educational programmes are often com- 
pared with ‘doing nothing’. Here ‘doing nothing’ is 
considered to be a reasonable alternative since 
patients participate in such programmes alongside 
their usual, mainly pharmacotherapeutic treatment 
without fear of an acute situation if the programme 
is omitted. Since adherence to long term pharma- 
cotherapy is known to be low in asthma and COPD 
patients, Windsor et al. [22], developed a standard- 
ized health education programme to increase therapy 
adherence. At 12 month follow-up, the experimental 
group of patients (n = 132) showed a significantly 
higher level of improvement in correct inhaler use, 
inhaler adherence, medication adherence (self re- 
ported and checked with a theophylline level test) and 
total adherence compared to the do-nothing control 
group patients (n = 135). Excluding intervention de- 
velopment costs, the programme costs $32.03 per 
patient. 
Deter [8] also compared the cost-effectiveness of 
health education combined with group coping 
therapy for working adult asthmatics with a do-noth- 
ing control group. He found a significant reduction in 
the number of working days lost and a non-signifi- 
cant reduction in the number of working days hospi- 
talized and number of visits to the general 
practitioner, resulting in estimated savings of DM 
1951 per patient. 
Few educational efforts directed at adults seem to 
have been evaluated economically. In an attempt to 
change this situation Wilson-Pessano et al. [21] report 
their plans for a cost-effectiveness study in which 300 
patients are to be randomly divided into 4 treatment 
groups: an individual self-management group, a 
group self-management group, a self-management 
information/attention control group and a data only 
control group. The emphasis will be on self-manage- 
ment practices, morbidity, functional impairment, 
medical regimen and the utilization and costs of 
services. 
Health education for children 
Educational programmes in children have been 
studied more widely. Three of these studies also 
considered cost-effectiveness [7, 10, 141. All three, by 
comparing programme costs with savings due to a 
decrease in emergency room visits, hospitalizations 
and drug use, reached the conclusion that educational 
programmes for children are cost-effective. When 
compared to a ‘do-nothing’ control group Fireman 
et al. [lo] have shown that health education directed 
at both the child and the parents resulted in a 
significant reduction in asthma attacks, school absen- 
teeism, emergency room visits and hospitalizations. 
Compliance with drug therapy was also better. The 
costs of additional drug use and the costs of the 
educational programme provided by a nurse-educa- 
tor were half the savings due to reduced hospitaliz- 
ations and emergency room visits, savings of $2920 
and $225 per child per year respectively. In a ran- 
domised trial, Lewis et al. [14] compared a detailed, 
small-group asthma care training programme di- 
rected at both children and their parents (n = 48) to 
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a control therapy consisting of a few large group 
sessions (n = 28). They estimated savings of approxi- 
mately $180 per child per year for those in the 
experimental group. Besides a significant reduction in 
emergency room visits and hospitalizations, they also 
found a significant reduction in parents’ reports of 
children’s dependency on adults for care and of 
children’s trouble with asthma as well as improved 
family communication. In the study by Clark et al. 
[7], no significant reductions in hospitalizations 
and emergency room visits were found when the 
complete experimental and ‘do-nothing’ control 
groups were compared. However when the com- 
parison was restricted to two subgroups, one of 
children with at least one hospitalization in the year 
preceding the intervention, the other to children with 
at least 1 hospitalization and 6 emergency room visits 
in the previous year, significant reductions and sav- 
ings were found. The authors might have drawn the 
conclusion that health education may only be cost- 
effective when directed at severely afflicted patients 
with at least one hospitalization a year. However they 
did not do so, because positive effects in terms of 
improved self management skills, school performance 
and school adjustment reported elsewhere have 
shown health education to be effective for wider 
groups. 
Pulmonary rehabilitation 
The continuation of the situation before the pro- 
gramme is the alternative to which Wright et al. [23] 
compared their pulmonary rehabilitation pro- 
gramme. Pulmonary rehabilitation can be defined as 
an individually tailored, multidisciplinary pro- 
gramme which, through accurate diagnosis, therapy, 
emotional support and education, stabilizes or re- 
verses the progress of the disease and seeks to return 
the patient to the highest possible functional capacity 
[29]. Wright et al. estimated the savings achieved by 
pulmonary rehabilitation due to the reduction in 
hospital days in the first year following the pro- 
gramme to be $217,610 for a group of 57 patients for 
whom follow-up data were available. Exercise ability 
also increased. The costs of the programme 
amounted to $66,462, resulting in net savings of 
$151,148 per year for these 57 patients. 
Providing exercise programmes and prescribing 
daily exercise alone is not enough. As with drugs, 
non-compliance with exercise is a common problem. 
Toevs et al. [20] studied the effects of using be- 
havioural programmes to improve compliance with 
an exercise programme. The control group was as- 
signed an exercise programme but did not receive a 
behavioural programme. Adding the behavioural 
programme to the exercise programme produced 
one additional quality adjusted life year at a cost 
of $24,256 per patient. Assuming that the effects will 
last for 2.5 years, the cost per QALY drops to 
$18,455. 
Domiciliary oxygen therapy 
‘Doing nothing’ is not a realistic alternative for 
oxygen therapy. Repeated hospitalizations or in the 
long run even admission to a nursing home could 
become necessary in the absence of this therapy. A 
study comparing oxygen therapy with the above 
mentioned alternatives is unlikely to be designed and 
conducted because of the overwhelming acceptance 
of oxygen therapy [30]. Its efficacy in terms of 
reduced mortality and improved neuropsychological 
function has been established by several clinical 
trials. Since it does not seem necessary to ask 
whether domiciliary oxygen is worthwhile per se, 
studies of oxygen therapy are concerned with the 
alternative ways of delivering the oxygen. In three 
studies [15, 16, 191 concentrator oxygen-a concen- 
trator is an electrically driven machine which ex- 
tracts oxygen from the air-has been compared to 
gas cylinder oxygen in order to determine the most 
efficient way of delivering oxygen at home. The first 
of these studies also added liquid oxygen to the 
comparison. Lowson et al. [15] explicitly state that 
the alternatives under consideration seem to be 
equally effective. This is confirmed by the finding of 
Strom et al. [19] that scores on the Sickness Impact 
Profile did not significantly differ between the 
groups treated with gas cylinder oxygen and concen- 
trator oxygen. Although quite different in their 
methodology and calculation of costs, all three stud- 
ies reached the overall conclusion that in most 
situations the concentrator was the least expensive 
method of delivering oxygen. In addition Strom 
et al. found that concentrators were easier and safer 
to handle and can be managed by the patient him or 
herself in most cases. 
Unlike cylinders, concentrators cannot always be 
hired, and the oxygen delivery and maintenance can- 
not thus be provided by the manufacturer. In that case 
large capital outlays may be needed from the health 
care sector at the start of a concentrator oxygen 
project. This is not only due to the high purchase price 
of the equipment but also to the need to establish a 
workshop facility from which the concentrators are 
maintained [15]. Where these large capital costs apply, 
concentrator oxygen therapy is more cost-effective the 
larger the number of patients served by this unit. 
Renting or purchasing concentrators Seems to make 
no difference to maintenance costs [ 161. 
Home care 
Home care is usually compared to alternatives 
which may well be substituted for it, such as insti- 
tutional care or doctor’s office care [S, 6,9, 171. Two 
studies [5,9] found no significant reductions in 
health care costs due to home care. Bergner et al. [S] 
randomly assigned homebound COPD patients aged 
40-75 to one of three groups: respiratory home care 
(n = 99), standard home programme (n = 102) or 
doctor’s office care without additional home nursing 
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services (n = 100). They found no significant differ- 
ence between the three groups in survival, pulmonary 
function, walking rate, activities of daily living, and 
scores on the General Well Being and the Sickness 
Impact Profile. The home care programmes even lead 
to additional health service utilization rather than to 
the substitution of ambulatory care for inpatient care. 
Also, the imputed costs for unpaid help for the 
respiratory and standard home care groups did not 
differ significantly from those for the office care 
group. The reason no cost reduction was found may 
be that Bergner et al. studied community-based home 
care programmes. Providing these programmes, as 
compared to hospital-based home care programmes, 
may imply less communication between community 
based nurses and the treating physician about services 
that could be substitutes for regular check ups at the 
hospital. 
Dranove [9], by comparing two hospitals, one with 
and one without a home care programme, showed 
that home care significantly substitutes for the last 
few days of a hospital stay and outpatient visits. 
Home care reduced the initial length of stay of 
patients older than 65 years suffering from cerebro- 
vascular disease (CVD) or COPD by 3.4 days and the 
number of clinic visits by 6.2 per patient. No re- 
duction in the number of emergency room visits was 
found. Despite this substitution Dranove found no 
significant reduction in overall hospital costs because 
of the relatively larger costs of the home care pro- 
gramme. 
Probably home care is more cost-effective in highly 
selected patient populations. For example, Campbell 
et al. [6] studied the effects of a hospital based home 
care programme in severe asthma, COPD or 
bronchiectasis patients showing substantial co-mor- 
bidity and frequent hospitalizations due to pulmon- 
ary disease. An additional inclusion criterion was the 
presence of a significant other in the home or commu- 
nity willing to assume the role of caretaker. When 
pre-programme costs were compared to programme 
costs, the overall health care savings were $328 per 
patient per month. Similarly, for respirator-depen- 
dent patients needing around-the-clock home care, 
Motwani et al. [17] found the costs of home care to 
be lower than the cost of care in the respiratory centre 
which was considered the only possible alternative for 
these patients. 
Aerosol delivery of bronchodilator drugs 
Two studies reported on the cost-effectiveness of an 
updraft nebulizer compared to a metered dose inhaler 
as alternative methods to delivery aerosol bron- 
chodilator drugs in hospitalized patients [ 11, 131. 
Both studies included the same indirect costs e.g. 
labour costs, medication costs and the cost of the 
devices. The randomized study by Jasper et al. [13] 
involved patients with exacerbated obstructive lung 
disease, most of whom were transferred to the pul- 
monary ward from the emergency room or intensive 
care units. They received bronchodilation treatment 
with metaprotenerol via therapist administered up- 
draft nebulization or via metered dose inhaler. The 
randomized cross-over study by Gay et al. [l l] in- 
volved intubated mechanically ventilated patients, 
some of whom may not have had obstructive lung 
disease [lo]. In the case of the intubated patients the 
nebulizer and the metered dose inhaler were attached 
to endotracheal tubes. Whereas Gay et al. performed 
a single treatment comparison, Jasper et al. assessed 
not only immediate response to bronchodilator drugs 
but also response during hospitalization and response 
at discharge from the hospital. In the first study no 
differences were found between the delivery methods 
so far as iso-recoil flows or side effects in terms of an 
increased heart rates. Jasaper et al. found no differ- 
ences between the delivery methods with respect to 
initial post-bronchodilator and discharge post-bron- 
chodilator FEV, (Forced Expiratory Volume in one 
second) and FVC (Forced Vital Capacity) and dur- 
ation of hospital stay. In addition, both studies found 
that the metered dose inhaler was more cost-effective 
than the updraft nebuliser, and may be substituted 
for it. According to Jasper et al. such a substitution 
would not be appropriate for patients in the intensive 
care unit or the emergency room. However, the 1990 
study by Gay et al. showed that the metered dose 
inhaler was also more cost-effective for these patients. 
The 198 1 Office of Technology Assessment report 
by Scheffler et al. [24] contained estimates of the cost 
of delivering aerosol medication in hospitalized 
patients using three different devices: an intermittent 
positive pressure breathing machine (IPPB), an ultra- 
sonic nebulizer and a simple aerosol generator. Equal 
effectiveness was assumed and supported by referring 
to several studies. The direct costs of labour, equip- 
ment, disposables and electricity were considered. 
Again simple aerosol treatment proved to be the least 
costly both as initial treatment and follow-up treat- 
ment. 
Mechanical ventilation 
When the IPPB is used for mechanical ventilation 
purposes where a patient’s breathing has totally 
ceased owing to the suppresion of brain activity, 
paralysis of the respiratory muscles, chest wall injury 
or acute and potentially reversible lung disease, its 
effectiveness is well accepted, and is similar to that of 
other mechanical aids to support the ventilatory 
function. In such cases ‘doing nothing’ would in- 
evitably lead to immediate death. Although the 
method is well-accepted, it remains a problem to 
select the patients most likely to benefit from pro- 
longed mechanical ventilation. Schmidt et al. [18] 
showed in their study that the cost of extending life 
for one year with mechanical ventilation varied from 
$2155 for COPD to $8026 per year of extended life 
for cardiac patients. Cost-effectiveness ratios were 
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considerably lower for patients with asthma and 
COPD largely because the mortality during hospital- 
ization was lower. Only the total non-physician 
charges of hospital care were included and a 
portion of the costs of the non-survivors in a diagnos- 
tic group was added to the costs of survivors in that 
group. 
Alpha-l Antitrypsin Replacement Therapy 
Congenital Alpha-l Antitrypsin (AAT) deficiency 
results in COPD. AAT can be replaced intravenously 
and this replacement therapy-the costs of which are 
estimated to be $30,000 per year-has been shown to 
improve levels of AAT in serum and epithelial tissue. 
However, clinical efficacy in slowing down COPD 
progression is unknown. Conducting a controlled 
trial would take a very long time due to the small 
number of potential beneficiaries. Therefore Hay 
et al. [12] took available data on congenital COPD 
incidence, prevalence, survival and costs of COPD 
treatment and applied it to a cost-effectiveness model 
of AAT replacement herapy in homozygous AAT- 
deficient COPD patients. A range of hypothetical 
efficacy values (expressed as a percentage of the 
survival rate of the normal population) was com- 
pared to the cost of AAT replacement herapy and 
other lifetime health care costs after the diagnosis of 
COPD. At an efficacy of 70%, the costs per life year 
saved would be between $28,000 and $72,000 depend- 
ing on patient age, sex and smoking status. Quality 
of life adjustment does not alter these results drasti- 
cally. 
OUTCOMES 
Sixteen of the 20 studies examined both the cost 
and the outcomes, using a great variety of outcome 
measures which can be classified into four main 
categories. More detailed information on the out- 
come parameters used and the significance of the 
effects measured by them can be found in the column 
‘main outcome measures’ and ‘results per outcome 
measure’ of Table 1. 
Clinical measures 
Clinical measures include physiological measures 
such as lung function parameters, physical measures 
such as exercise tolerance and walking distance, and 
laboratory assessments. Lung function parameters 
are essential for monitoring the course of asthma and 
COPD, because of their known relationship to dis- 
ease prognosis [31]. However, interventions such as 
health education, pulmonary rehabilitation and home 
care [7,8, 321 do not seem to alter spirometric data. 
Therefore, most of the studies dealing with these 
interventions do not include lung function par- 
ameters. Relevant effects of health education are 
usually measured in terms of increased knowledge, 
improved skills, improved attitude towards asthma 
and reduced health care utilization. The effects of 
pulmonary rehabilitation are usually measured in 
terms of improved oxygen consumption and physical 
measures uch as walking distance and exercise toler- 
ance [23]. 
An evaluation confined to a fairly narrow assess- 
ment of physiological status, as in Jasper et al. [13] 
gives little information about patients’ overall func- 
tioning. Moreover, measures such as walking dis- 
tance look meaningful and easy to analyze, but may 
bear only a loose relation to the patient’s underlying 
condition. It has been shown that a therapy which 
produces changes in clinical status may not produce 
corresponding changes in quality of life [3340]. 
Other factors such as the patient’s attitude, expec- 
tations, emotions, ability to adapt, and sociological 
factors may intervene. Since it is likely that clinical 
and quality of life measures address different aspects 
of the disease, a meaningful outcome assessment 
should include both. 
Disease -specific quality of life measures 
The studies which did use quality of life measures 
of outcome such as Lewis et al. [14] and Strom et al. 
[19], who even developed a study-specific question- 
naire, generally present a pattern of different aspects 
of quality of life directly related to having the particu- 
lar disease. Such a heterogeneous description of 
changes in disease-specific quality of life may be 
sufficient, particularly when the results all point in the 
same direction and no comparison with interventions 
in other patient populations is envisaged. The ration- 
ale for using such disease-specific outcome measures 
lies in their potential for increased responsiveness. 
Although disease-specific measures may be more 
sensitive to disease-specific changes, they lack general 
reference points which enable across-programme 
comparisons. 
Generic quality of life measures 
In order to allow such comparisons and in order to 
facilitate the interpretation of the heterogeneous re- 
sults one may want to combine them into a few 
subdimension scores or into one overall summary 
score, called a health profile and a health index 
respectively. Both Strom et al. [19] and Bergner et al. 
[5] attempted to quantitatively assess the relative 
importance of their information using a measure of 
the overall quality of life such as the SIP. The SIP is 
a generic measure of health-related ysfunction in 12 
areas of activity: ambulation, mobility, body care and 
movement, social interaction, emotional behaviour, 
alertness behaviour, communication, work, eating, 
sleep and rest, household management and recreation 
and pastimes. Besides 12 category scores, it provides 
an overall score, a psychosocial dimension score and 
a physical dimension score. 
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Utilities and QALYs 
The primary objective of indices and profiles is an 
overall summary description of health status. One 
may go one step beyond the description by explicitly 
valuing the summarized descriptions of the changes 
in health status. This is particularly necessary when 
measures of different dimensions of the quality of life 
are of different size or sign. By means of utility 
measurement such positive and negative effects may 
be evaluated, balanced and integrated in an overall 
value for the quality of life, the so called utility. Toevs 
et al. [20], who used the Quality of Well-Being Scale 
developed by Kaplan and Bush [41,42], converted the 
quality of life gains into a single index of so-called 
‘well-years’ or QALYs. At baseline and follow-up 
each patient’s health state was classified into 1 of 43 
mutually exclusive levels of functioning. The levels 
were obtained by combining different levels of mobil- 
ity, physical activity, social activity and different 
symptomatic disturbances. Then utilities were as- 
signed to each patient’s health state. These utilities, 
which reflect the preference weights for the various 
health states, were elicited from the general popu- 
lation. Finally each patient’s utility was multiplied by 
the number of years the effects were expected to last. 
This technique is relatively new and still rarely used 
in the domain of chronic diseases, because it is 
expected to be insensitive to slight improvements (or 
reductions) in health status [43]. But, particularly 
because economic evaluation studies aim at providing 
information for overall comparisons between inter- 
ventions, QALYs are promising outcome measures, 
even though a number of methodological problems 
need to be solved. However, the study by Toevs et al. 
shows this approach to be feasible in evaluating 
treatment for a common chronic condition such as 
COPD. 
Sometimes the outcome assessment is restricted 
solely to the intermediate effects of treatment on 
reductions in health services use. Although these 
outcomes can be measured solely in volume terms, 
they are usually measured in monetary units and 
incorporated in the numerator of a cost-effectiveness 
ratio, by the calculation of net incremental costs. The 
same is true for absence from work due to illness, 
although the costs associated with sick leave are often 
presented separately. Therefore we describe them 
more thoroughly in the next section. Like absence 
from work in adults, school absenteeism is an import- 
ant outcome measure in studies involving children. 
Only Fireman et al. [9] studied the impact of health 
education on school absenteeism, finding that it was 
reduced ten-fold. 
COSTS 
In the reviewed studies four main categories of 
costs could be identified: 
Costs of organizing and operating a particular health 
care programme 
The studies dealing with alternative ways of deliv- 
ering aerosol bronchodilation [ 11, 13,241 all adopt an 
administrator’s perspective in which only programme 
costs are considered. All found that delivering medi- 
cation through a metered dose inhaler is the least 
expensive, mainly because of lower labour costs but 
also because of lower equipment costs. The compari- 
son of alternative ways of delivering oxygen is also 
restricted to programme costs [15, 16, 191. Strom 
et al. [19] even restricted their analysis to annual 
running cost per patient-which were twice as high 
for gas cylinders as for concentrators-without con- 
sidering set-up costs. However set-up costs can be 
very important, as can be seen from the studies of 
domiciliary oxygen therapy, by McKeon et al. [16] 
and Lowson et al. [15], which were described above. 
In evaluating alternative ways of delivering aerosol 
bronchodilation or oxygen, a restriction to pro- 
gramme costs may be justified, since equal effective- 
ness between the delivery methods is assumed and no 
change in the use of other health services is to be 
expected. However in the study by Windsor et al. [22] 
of health education this may be too limited a scope. 
If health education is as effective in increasing medi- 
cation compliance as Windsor et al. showed, than a 
decrease in the use of other health care services such 
as visits to doctors’ surgeries may be expected and 
should have been measured. 
When calculating costs associated with providing a 
particular programme, resources that are used solely 
for the purpose of the evaluation study itself have to 
be identified and subtracted from the program costs, 
but few studies do so. Clark et al. [7] and Lewis et al. 
[ 141 are exceptions, in separating the costs of evaluat- 
ing the educational programmes from routinely in- 
curred costs. Unfortunately, these studies also 
excluded programme development costs, which 
should have been included. 
Casts qf utilization of other health seroices 
With the exception of the study by Windsor et al., 
all the studies concerning health education 
[7, 8, 10, 14. 211 or home care [5, 6,9, 171 do include 
the costs of other health services. They are particu- 
larly interested in savings as a result of reduced 
emergency room visits, clinic visits, and hospitaliz- 
ation days. The latter was of prime importance in the 
two studies dealing with pulmonary rehabilitation 
[20, 231. 
It frequently occurs that the mean cost of hospital- 
ization is very much affected by a small number of 
expensive cases. As a result, differences in the net 
costs of two programmes may be influenced by only 
a few cases. Since this reduces statistical power, 
testing differences in hospitalization costs is difficult. 
Savings in health care resource use may be either 
compared with the programme costs or deducted 
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from the programme costs in order to calculate the 
net cost of the intervention. Clarke et al. [7] used the 
first approach and found that for children who had 
been hospitalized during the year preceding the pro- 
gramme, health education reduced emergency room 
visits and hospitalizations, saving $11.22 for every 
$1 .OO spent on health education. Toevs et al. [20] used 
the second approach and calculated the net costs of 
the intervention by deducting the hospital costs which 
were saved from the direct costs of the behavioural 
intervention programme. 
Out-of-pocket expenses of patients and their families 
The most comprehensive calculation of COPD 
health care costs is provided by Bergner et al. [5]. 
They include, from a societal viewpoint, all relevant 
inpatient and outpatient costs, which they obtained 
from several sources such as patients, bills, receipts, 
third party payers, pharmacists etc. Like Deter [8], 
they also included out-of-pocket payments by 
patients, mainly travelling expenses. A third study 
also included costs falling on patients, but a separate 
identification of these costs is not provided [15]. 
The loss of productivity due to absence from work, 
imputed volunteer time or family time 
The first three categories of costs are often referred 
to as direct costs. In economic evaluation jargon the 
term indirect costs refers primarily to production 
losses due to absence from work because of illness. 
Measuring the reduction in days of absence due to 
illness is especially relevant in asthmatic patients and 
patients with mild airflow limitation. Measuring the 
impact of treatment on employment status may not 
be very relevant for patients with severe chronic 
airflow limitation, since this mostly concerns rela- 
tively older patients who have only a few work years 
remaining and who would probably continue to 
decrease in work ability during those years because of 
their lung disease. Asthma and COPD interventions 
can only make an impact in terms of returning people 
to the work force for patients whose lung disease is 
identified at a younger age, when the disease is less 
progressive. Although relevant for less severely 
afflicted patients, measuring the impact of treatment 
on employment status may be difficult. Factors such 
as the national unemployment rate, duration of un- 
employment, age etc. may influence the percentage of 
patients returning to work. The study by Deter [8], 
which involved only working adult asthmatics, is the 
only one to consider savings due to a reduced number 
of working days lost. Loss of productivity due to 
absence from work on days of group therapy was 
included in programme costs. Production loss was 
estimated by means of individual real market wages. 
Earnings are commonly used but also frequently 
criticized measures of production losses, since it is 
questionable whether production is actually lost, 
especially in times of unemployment. Also, as a 
consequence of this approach, higher priority in the 
access to care would be given to high income earners. 
Perhaps a more realistic but difficult to perform 
alternative would be to consider the real costs to 
employers arising from the replacement and re-edu- 
cation and training of employees. Drummond et al. 
[26] advise that productivity gains and losses should 
not be included in calculating the net costs of an 
intervention because of the problem of the differential 
valuation of time for those in and those out of the 
labour force. It certainly seems preferable to count 
changes in productivity separately from other costs 
and outcomes. One may also measure restricted 
activity days for patients who are not in the work 
force and estimate their productivity loss by, for 
example, using the wages paid employees would get 
when performing the same work. Such a proxy is used 
by Bergner et al. [S], when they estimated the imputed 
costs of unpaid help by family or friends using the 
costs of home health aides. 
Costs us expenditures and charges 
In general, costs refer to the sacrifice made when a 
given resource is consumed, and not to expenditures 
only. Wright et al. [23] should not have excluded the 
services for which members of the rehabilitation staff 
donated their time from the programme costs. 
Although donated time requires no expenditures, it 
does involve resource use, because these staff mem- 
bers cannot put their time into alternative services. 
Although detailed costing methodology is often 
lacking it can be seen that a majority of studies still 
use average costs (per hospital day, per home nursing 
visit, average wages etc.) or charges. This may not 
reflect the real costs borne by society for a particular 
treatment. The average daily hospital costs are likely 
to be a poor guide for the savings in resource use if 
hospital stays were shortened, since resource use is 
typically higher in the first part of a patient’s hospital 
stay [44]. Because home nursing can be a substitute 
only for the last few days of a hospital stay, Dranove 
et al. [9], in studying the impact of a home nursing 
department on the savings in hospital costs, thought 
it appropriate to include only the costs of routine care 
and clinical laboratory work in the average daily 
hospital cost. In comparing respiratory centre care 
with home care, Motwani et al. [17] showed that the 
actual costs of ventilator dependent respiratory 
centre care were much higher than Medicaid reim- 
bursement rates. This was because higher levels of 
staff were required in the respiratory centre than in 
the other hospital departments, although the reim- 
bursement rates were the same. Based on charges 
Motwani et al. concluded that home care was more 
cost-effective than respiratory centre care. When 
based on actual costs, home care would become even 
most cost-effective. Sometimes, using the amounts 
charged as a proxy for costs may not introduce a 
stystematic bias into identifying differences between 
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treatment programmes, although it still risks mis- 
stating the magnitude of any cost differences. 
An incremental analysis, as for example in Lowson 
et al. [ 151, does not consider costs which are common 
to both alternatives. It deals therefore with differen- 
tial costs, rather than with the total treatment cost. 
An incremental analysis may be sufficient to support 
decisions concerning only the programmes studied. 
But if a comparison with other alternatives, perhaps 
outside the medical domain of the intervention is 
wanted, then total costs are needed. 
Discounting and sensitivity analysis 
Sound economic methodology also prescribes that 
costs and benefits occurring at different times should 
not just be added or subtracted, but rather expressed 
in terms of their equivalent values at one point in 
time. This adjustment procedure is called discounting 
and usually involves calculating the net present values 
of future costs and outcomes using the same discount 
rate. The discounting of health effects is not uncon- 
troversial (for a recent debate see Refs [4547]). In 
most of the studies, discounting was irrelevant, be- 
cause no long term consequences were studied. Hay 
et al. [12], Lowson et al. [15] and Toevs et al. [20] have 
applied discounting. They also studied the influence 
of the application of various discount rates (O%, 5%, 
10%) in a sensitivity analysis. Both Lowson et al. and 
Toevs et al. concluded that the various discount rates 
have little influence on the cost-effectiveness ratios 
found in their studies because only a limited time 
period was considered. Discounting did have a larger 
effect on the evaluation of Alpha-l Antitrypsin re- 
placement therapy, because here lifetime treatment 
costs and outcomes were estimated [12]. In general, 
programmes that require current investments to 
achieve benefits far in the future are more strongly 
affected by the choice of a discount rate. Therefore a 
screening programme for Alpha-l Antitrypsin defi- 
ciency could be even more affected by the choice of 
discount rate than is Alpha-l Antitrypsin replace- 
ment therapy itself. 
Each study should perform a sensitivity analysis to 
show the influence of several assumptions on the 
overall cost-effectiveness ratio. Hay et al. [12] have 
provided an exemplary sensitivity analysis, in which 
they show the effects of a 40% increase and decrease 
of not only discount rates but also of annual costs of 
COPD care, the quality of a restricted activity day, 
the median survival from onset of COPD and annual 
costs of AAT treatment. The cost-effectiveness ratio 
proved to be most sensitive to the assumptions about 
the latter two factors. 
As Guyatt et al. [27] point out, it is important to 
analyze the costs (and outcomes) from a broad 
perspective. This means the inclusion of all four 
categories of costs, as far as they are relevant. This 
may also mean the consideration of various view- 
points (government, Ministry of Health, patients, 
health care providers) if one wants to understand 
more fully the gains and losses to key actors in the 
system. 
QUALITY OF THE EFFECTIVENESS EVIDENCE 
It is argued by Drummond [48] that economic 
appraisals should be based on reliable evidence of 
effectiveness. It is certainly possible to perform a 
good economic appraisal without actually comparing 
two or more patient groups. But especially in that 
case, effectiveness information based on previous 
good quality studies should be provided. Good 
examples of such studies are the ones by Lowson 
et al. [15], Schmidt et al. [18] and Scheffler et al. [24]. 
If no such information is available a range of possible 
effectiveness levels should be considered to give some 
information on the sensitivity of the cost-effectiveness 
to these levels. This was done by Hay et al. [12]. 
However, Motwani et al. [17] used the opinion of 10 
patients and their medical professionals: this would 
seem to be insufficient evidence to support the as- 
sumption that respiratory centre care was the only 
appropriate substitute for home care. 
Ten out of the 20 economic appraisals actually 
compared two or more patient groups 
[5, 7, 8, 10, 13, 14, 19-221, and in 7 of these 10 studies 
patients were randomly divided into an experimental 
and a control group [5,7, 13. 14,2&22]. In exper- 
imental studies that concentrate on the impact of 
health education or pulmonary rehabilitation, an 
observed effect could partly be due to the attention 
the experimental group received. Giving a placebo to 
a control group in studies other than those concern- 
ing pharmacotherapy is considered to be difficult. 
However, Wilson et al. [21] have tried to control for 
the personal attention given to the experimental 
groups by designing a study which incorporates two 
control groups, one in which patients get the same 
written information as the experimental group but no 
personal attention, and one in which patients get no 
information or attention at all. The former is called 
an attention-placebo [27]. Lewis er al. also provided 
their control group with the same knowledge as the 
experimental group. However the knowledge was 
provided in impersonal large group sessions, whereas 
the experimental group received more personal atten- 
tion in small groups. 
Three studies were before-and-after comparisons 
of just one patient group [6, 16,231. Because of this 
design, the favourable outcomes which both Camp- 
bell et a/. [6] and Wright et al. [23] found cannot solely 
be attributed to the intervention. Other factors such 
as the natural course of the disease or regression 
towards the mean might have explained at least part 
of the improvement. 
The study by Gay et al. [l l] used a cross-over 
design, which is used mainly to enhance the power of 
the statistical comparisons. In the case of different 
aerosol delivery methods, no carry-over effect (in 
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which the effect of administering albuterol by means 
of a metered dose inhaler in the first period influences 
the effect of administering it by means of an updraft 
nebulizer in the second period) is likely, since a 
wash-out period of 4 hr was allowed between the first 
and the second delivery. 
Drawing conclusions based on a comparison of 
two health care institutions is extremely difficult 
because of the large number of biases that can occur. 
Dranove [9] tried to avoid the bias that might have 
resulted from the comparison of two hospitals-one 
with and the other without a home care pro- 
gramme-by taking younger patients who were not 
eligible for home care as a kind of control group. 
Instead of comparing the mean length of hospitaliz- 
ation for elderly patients in the two hospitals, he 
compared the difference in the length of hospitaliz- 
ation of younger and older patients in one hospital 
with the difference in the other hospital. Thus he 
partly controlled for differences between patient 
populations. Despite this, he could not completely 
rule out the possibility that differences between the 
hospitals affected his study results. 
Some studies are of poor quality due to the in- 
adequate sample size. These studies may not have the 
power to detect clinically significant differences. The 
fact that Deter [8] and Gay et al. [l 1] found no 
significant difference between the experimental and 
control group in terms of hospitalization days and 
visits to the primary physician may be due to the 
small sample size. Deter, moreover, divided patients 
(n = 57) randomly into an experimental and a control 
group before applying the inclusion criterion that 
patients had to be employed. Therefore only 22 
patients remained, of whom only 7 patients in the 
experimental group and 8 in the control group 
finished the whole study. Large numbers of with- 
drawals can cause serious analysis problems, es- 
pecially when withdrawal is due to a deterioration 
only occurring in the control group. When deterio- 
ration also leads to higher health care cost, the 
cost-effectiveness ratio will be overestimated. In the 
study by Clark et al. [7] more than 20% of the 
patients were lost to follow-up, and in the study by 
Bergner et al. [5] 21% were lost. Since neither pro- 
vided a comparison of these patients with the patients 
who completed the study it is impossible to say 
whether this influenced the cost-effectiveness ratio in 
any way. 
Obviously, the most reliable effectiveness evidence 
is that produced by a well-designed randomized 
controlled trial. Performing an economic evaluation 
alongside such a trial entails a number of problems. 
Even those trials which are directly concerned with 
assessing the effectiveness rather than the efficacy of 
the therapy may still be conducted under such ra- 
refied experimental conditions that costs and out- 
comes will be quite different to those under normal 
conditions [49]. There remains a need to assess ther- 
apies as they are routinely delivered in actual daily, 
practice. 
CONCLUSIONS AND DISCUSSION 
Although central governments and third party 
payers increasingly stress the need to set priorities on 
the basis of efficiency considerations, there have been 
only 20 economic appraisals of asthma or COPD-in- 
terventions published in the last 11 years, most of 
them American. Because of the small number of 
studies per subject, the considerable differences in the 
measurement of both costs and outcomes and other 
methodological issues, only very preliminary con- 
clusions can be drawn. 
Health educational programmes seem to be rela- 
tively inexpensive and in children they seem to result 
in savings due to less hospitalizations and emergency 
room visits. Moreover there seem to be indications 
for improvements in attitude, self-management skills 
and school absenteeism. The study by Windsor et al. 
is the only economic appraisal dealing with health 
education in adults offering guidance for a cost-effec- 
tive improvement in compliance behaviour. Toevs 
et al. also found evidence of increased compliance 
when a behavioural programme was added to an 
exercise programme. The costs per QALY for this 
intervention were more than $24,000. The con- 
clusions that can be drawn from the studies of 
inpatient aerosol drug delivery methods and oxygen 
delivery methods are perhaps the most straight-for- 
ward, the first indicating that the simple metered dose 
inhaler is the most cost-effective and the latter sup- 
porting the concentrator option, provided that the 
number of patients to be served is not too small. The 
results of the studies dealing with home care point in 
different directions. However, there seems to be evi- 
dence in favour of hospital-based home care pro- 
grammes directed at highly selected, very severely 
afflicted patient groups, as compared to community- 
based home care programmes in wide patient 
populations. 
Physicians are responsible not only for providing 
an optimal therapy from a medical viewpoint, but 
also for providing an efficient therapy. More cost- 
effectiveness evidence is required on the various 
asthma and COPD interventions described above. 
This is especially true for the relatively expensive 
treatments such as pulmonary rehabilitation and 
home care. Moreover, in two particular areas cost- 
effectiveness evidence seems to be totally lacking. The 
most striking is the lack of any cost-effectiveness 
study concerning pharmacotherapy, although this is 
the main intervention in asthma and COPD manage- 
ment. Of all the bronchodilators that are used in 
current practice, we do not know which ones are 
the most efficient for patients exhibiting particu- 
lar clinical symptoms. We do not know whether the 
extra benefits of combined bronchodilator and 
corticosteroid therapy compared to bronchodilator 
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monotherapy outweigh the extra costs. We argue 
that-in addition to the relatively large number of 
effectiveness studies-there is a need for subjecting 
these relatively ‘low cost’ therapies to a thorough 
economic evaluation, since more than 7% of total 
drug sales in the Netherlands are related to asthma 
and COPD management and because it involves so 
many patients. In the future, cost-effectiveness evi- 
dence will increasingly be asked for as a complement 
to the clinical evidence of the safety and efficacy of 
new drugs. Such evidence may influence the price- 
setting of new drugs and support cost-reducing thera- 
peutic substitution for already existing drugs. 
A second important area in which information is 
totally lacking is that of diagnostic technologies. For 
example, in some countries an economic evaluation 
of spirometry would be of value in guiding decisions 
about whether or not spirometry should be made 
available too for general practitioners. Similarly, 
some countries are considering screening for Alpha-l 
Antitrypsin deficiency. This decision should be based 
on a thorough, perhaps theoretical cost-effectiveness 
analysis, in particular since the number of patients 
with Alpha-l Antitrypsin deficiency is relatively small 
and replacement therapy is relatively expensive. For 
information on the costs and benefits of such technol- 
ogies to be useful, it should become available before 
the technologies are diffused throughout the health 
care system (Ref. [50]). 
Economic appraisals cannot be expected to have an 
influence on decision-making until the methodologi- 
cal quality of the studies is adequate. We have shown 
that there is still room for improvement. It is difficult 
to compare the results of various cost-effectiveness 
studies, because the analyses are not conducted ac- 
cording to uniform, accepted methodological stan- 
dards. As these conditions are being met, economic 
evaluation studies can contribute to improved 
efficiency in delivering asthma and COPD care. 
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